Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis | 2024 | Pharmacological Research |
Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis | 2023 | Diabetology & Metabolic Syndrome |
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review. | 2023 | Expert Review of Clinical Pharmacology |
Effects of GLP-1 receptor agonists on neurological complications of diabetes. | 2023 | Reviews in Endocrine and Metabolic Disorders |
Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis. | 2023 | Medicine |
An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression | 2022 | The Journal of Clinical Endocrinology & Metabolism |
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. | 2022 | Cardiovascular Diabetology |
Semaglutide for the treatment of type 2 Diabetes Mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes. | 2022 | Diabetes & Metabolic Syndrome |
The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. | 2022 | Contemporary Clinical Trials Communications |
Once-daily oral semaglutide versus injectable glp-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis. | 2021 | Diabetes Therapy |
Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. | 2021 | Diabetes Research and Clinical Practice |
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. | 2020 | Annals of Internal Medicine |
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. | 2020 | The Journal of Clinical Endocrinology & Metabolism |
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. | 2019 | The lancet. Diabetes & endocrinology. |
Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis | 2019 | Diabetes & Metabolism |
Asian subpopulations may exhibit greater cardiovascular benefit from long-acting glucagon-like peptide 1 receptor agonists: a meta-analysis of cardiovascular outcome trials. | 2019 | Diabetes & Metabolism Journal |
Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis | 2019 | BMJ Open |